Therapies, Treatments, and Procedures

Page 1 of 512345

February 27, 2017

Bright Flash Retinal Photography–a Thing of the Past

Posted in: Latest News, Therapies, Treatments, and Procedures

by Dan Roberts (Macular Degeneration Support) and Liz Trauernicht (Macular Degeneration Foundation) OCT and nonmydriatic technologies are lessening discomfort and risk of eye exams. MD Support and MD Foundation communicate with thousands of patients who undergo periodic eye exams for diagnosis and treatment of macular degeneration, glaucoma, diabetic retinopathy, and other chronic diseases. Many have
read more »

January 6, 2017

Lucentis® Approved for Myopic Macular Degeneration

Posted in: Latest News, Research and Developments, Therapies, Treatments, and Procedures

Genentech has announced FDA approval for Lucentis® as a treatment for patients with choroidal neovascularization (CNV) resulting from myopic macular degeneration (MMD), also known as myopic degeneration. Severe myopia (near-sightedness) can cause uncorrectable central vision impairment, and it may advance to total central vision loss from CNV, which is growth and leakage of blood vessels
read more »

June 9, 2016

For Some, Switching ANTI-VEGF Treatments Midstream Could Be Harmful

Posted in: Latest News, Research and Developments, Therapies, Treatments, and Procedures

Switching from Lucentis to Eylea could result in worsening of the retinal condition of some people with wet (exudative) AMD. Since the advent of anti-VEGF drug treatments for wet AMD, research has verified that blood vessel growth and leakage (neovascularization) usually diminishes in patients who are switched from either Lucentis or Avastin to Eylea. A small
read more »

May 3, 2016

AMD Since Anti-VEGF

Posted in: Latest News, Therapies, Treatments, and Procedures

A National Eye Institute (NEI) study* confirms that anti-VEGF treatments have greatly improved the prognosis for patients with the wet form of age-related macular degeneration (wAMD) during the past decade. In the study of nearly 650 people, half still had vision 20/40 or better, typically good enough to drive or to read standard print, after five years of treatment with
read more »

November 16, 2015

Iluvien Similar to Anti-VEGF Drugs as Treatment for Diabetic Retinopathy

Posted in: Latest News, Research and Developments, Therapies, Treatments, and Procedures

On February 16, Charles C. Wykoff, MD, PhD, announced to the American Academy of Ophthalmology annual meeting that Iluviuan (fluocinolone acetonide) treatment, after 1.3 injections over 3 years in the FAME trials, “significantly reduced progression to prolific diabetic retinopathy from 31% to 17%, a similar reduction as observed with monthly anti-VEGF treatments.” Iluvian (Alimera Sciences)
read more »

November 16, 2015

Lucentis effective for proliferative diabetic retinopathy

Posted in: Latest News, Therapies, Treatments, and Procedures

NIH-funded clinical trial marks first major advance in therapy in 40 years A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy. The trial, conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) compared Lucentis with a type of laser
read more »

April 3, 2015

Phase 2 Stem Cell Trial To Be Initiated

Posted in: Latest News, Therapies, Treatments, and Procedures

Ocata Therapeutics, Inc. (now owned by Acucela) announced on March 31, 2015 that the company has completed dosing of its Phase 1/2 studies for dry age-related macular degeneration (AMD) and Stargardt’s Macular Degeneration (SMD). A total of 38 patients have been safely dosed. The 200,000 cell cohort, the highest level planned, was successfully completed, paving
read more »

February 7, 2015

FDA approves Lucentis to treat diabetic retinopathy in patients with diabetic macular edema

Posted in: Latest News, Therapies, Treatments, and Procedures

The U.S. Food and Drug Administration announced today that they have expanded the approved use for Lucentis 0.3 mg (Genentech) to treat diabetic retinopathy in patients with diabetic macular edema. The FDA previously had approved Lucentis to treat DME and macular edema secondary to retinal vein occlusions, both of which cause fluid to leak into
read more »

September 30, 2014

FDA Approves Two Extended-Release Drug Therapies For DME

Posted in: Latest News, Therapies, Treatments, and Procedures

By Dan Roberts Implants devised by two different companies for treatment of diabetic macular edema (DME) have been approved by the FDA for use in the United States. The companies are Allergan and Alimera, and the new drugs are Ozurdex and Iluvien respectively. Both drugs are corticosteroids that have demonstrated effectiveness in the treatment of
read more »

April 29, 2014

Experimental Therapies for CSR

Posted in: Research and Developments, Therapies, Treatments, and Procedures

by Dan Roberts April 2014 Updated September 8, 2015 Research has shown that corticosteroids produced by the body (endogenous) and administered externally (exogenous) can raise adrenaline levels, which can harm the central retina. Some people have high levels of endogenous steroids that can lead to a condition called central serous retinopathy (CSR), aka central serous
read more »

Page 1 of 512345

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann